Holen Sie sich die Stockscreener-App
11.14
2.28%
-0.26
Schlusskurs vom Vortag:
$11.40
Offen:
$11.11
24-Stunden-Volumen:
1.84M
Relative Volume:
0.63
Marktkapitalisierung:
$1.50B
Einnahmen:
$66.50M
Nettoeinkommen (Verlust:
$-100.52M
KGV:
-12.15
EPS:
-0.9165
Netto-Cashflow:
$-146.77M
1W Leistung:
-8.69%
1M Leistung:
-5.99%
6M Leistung:
+61.45%
1J Leistung:
+411.01%
1-Tages-Spanne:
$10.95
$11.31
1-Wochen-Bereich:
$10.90
$13.60
52-Wochen-Spanne:
$1.03
$13.60
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
11.14 | 1.54B | 66.50M | -100.52M | -146.77M | -0.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4%Here's What Happened - MarketBeat
Tango Therapeutics (TNGX) Price Target Increased by 11.32% to 15.19 - Nasdaq
Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79% - Markets Mojo
Tango Therapeutics Achieves 423.87% Return, Emerges as a Multibagger Stock in Biotechnology Sector - Markets Mojo
Investment Report: Is Tango Therapeutics Inc in a long term uptrendJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year HighHere's Why - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho - Defense World
Mizuho Initiates Coverage of Tango Therapeutics (TNGX) with Outperform Recommendation - Nasdaq
Tango Therapeutics stock hits 52-week high at 13.5 USD - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Coverage Initiated at Mizuho - MarketBeat
Mizuho initiates Tango Therapeutics stock with outperform rating By Investing.com - Investing.com Nigeria
Mizuho initiates Tango Therapeutics stock with outperform rating - Investing.com
Risk Hedge: Is Columbus Acquisition Corp being accumulated by smart moneyWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
FOMO Trade: How does Tango Therapeutics Inc correlate with NasdaqMarket Performance Summary & Consistent Profit Alerts - baoquankhu1.vn
Tango Therapeutics (TNGX) to Release Earnings on Thursday - MarketBeat
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences - Bitget
Readystate Asset Management LP Trims Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) - simplywall.st
Is Tango Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - mfd.ru
Is Tango Therapeutics Inc. a strong candidate for buy and holdTrade Signal Summary & Stock Market Timing Techniques - mfd.ru
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat - MarketBeat
Insiders At Tango Therapeutics Sold US$727k In Stock, Alluding To Potential Weakness - 富途牛牛
Tango Therapeutics stock hits 52-week high at $13.47 By Investing.com - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighShould You Buy? - MarketBeat
Tango Therapeutics stock hits 52-week high at $13.47 - Investing.com
Can Tango Therapeutics Inc. be recession proofJuly 2025 Intraday Action & Weekly Setup with ROI Potential - mfd.ru
TNGX: Pivotal and combination trial data for vopimetostat, plus pipeline updates, are expected this year - TradingView
TNGX: Major clinical milestones for vopimetostat and pipeline updates are expected this year - TradingView
Published on: 2026-02-12 23:58:23 - baoquankhu1.vn
Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $14.80 - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim Keeps Their Buy Rating on Tango Therapeutics (TNGX) - The Globe and Mail
Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Guggenheim Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Tango Therapeutics CFO sells $126,530 in TNGX stock By Investing.com - Investing.com UK
Tango Therapeutics CFO sells $126,530 in TNGX stock - Investing.com
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 18,452 Shares of Stock - MarketBeat
Weber Barbara, director at Tango Therapeutics, sells $374k in TNGX stock - Investing.com Canada
Commit To Purchase Tango Therapeutics At $10, Earn 25.9% Annualized Using Options - Nasdaq
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Can Tango Therapeutics (TNGX) climb 37.28% to reach the level Wall Street analysts expect? - MSN
Great Lakes Advisors LLC Invests $3.56 Million in Tango Therapeutics, Inc. $TNGX - MarketBeat
VIX Spike: Will Tango Therapeutics Inc benefit from rising consumer demandMarket Risk Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues - simplywall.st
Analysis Recap: Can Tango Therapeutics Inc be recession proof2025 Sector Review & Stepwise Swing Trade Plans - baoquankhu1.vn
Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) Target Price at $13.00 - Defense World
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics stock hits 52-week high at 12.65 USD - Investing.com India
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):